{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:08:49Z","timestamp":1789765729129,"version":"4.0.1"},"reference-count":35,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,6,18]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>DFX-DFO combination followed by DFX monotherapy led to a meaningful decrease in myocardial and liver iron in severe siderosis patients. Substantial liver iron reduction may be helpful in patients needing rapid control of liver iron (eg, pretransplant or planned pregnancy).<\/jats:p>","DOI":"10.1182\/blood-2014-07-586677","type":"journal-article","created":{"date-parts":[[2015,5,2]],"date-time":"2015-05-02T01:22:28Z","timestamp":1430529748000},"page":"3868-3877","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":78,"title":["Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload"],"prefix":"10.1182","volume":"125","author":[{"given":"Yesim","family":"Aydinok","sequence":"first","affiliation":[{"name":"Department of Pediatric Hematology, Ege University Hospital, Izmir, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis","family":"Kattamis","sequence":"additional","affiliation":[{"name":"First Department of Pediatrics, University of Athens, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Domenica","family":"Cappellini","sequence":"additional","affiliation":[{"name":"Universit\u00e1 di Milano, Ca Granda Foundation Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"El-Beshlawy","sequence":"additional","affiliation":[{"name":"Department of Hematology, Pediatric Hospital, Cairo University, Cairo, Egypt;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Origa","sequence":"additional","affiliation":[{"name":"Ospedale Regionale per le Microcitemie, University of Cagliari, Cagliari, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Elalfy","sequence":"additional","affiliation":[{"name":"Thalassemia Center, Children's Hospital, Ain Shams University, Cairo, Egypt;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurdanur","family":"Kilin\u00e7","sequence":"additional","affiliation":[{"name":"Medical Facility, Cukurova University, Adana, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silverio","family":"Perrotta","sequence":"additional","affiliation":[{"name":"Department of Woman, Child and of General and Specialist Surgery, I\u00b0Policlinico II\u00b0Universit\u00e0 di Napoli, Naples, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Karakas","sequence":"additional","affiliation":[{"name":"Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vip","family":"Viprakasit","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Thalassemia Center, Siriraj Hospital, Mahidol University, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Habr","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niculae","family":"Constantinovici","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwu","family":"Shen","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Porter","sequence":"additional","affiliation":[{"name":"Department of Hematology, UCL Cancer Institute, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"20","key":"2019111819264531000_B1","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1161\/CIRCULATIONAHA.109.874487","article-title":"Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major.","volume":"120","author":"Kirk","year":"2009","journal-title":"Circulation"},{"issue":"9","key":"2019111819264531000_B2","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2013.083634","article-title":"International survey of T2* cardiovascular magnetic resonance in \u03b2-thalassemia major.","volume":"98","author":"Carpenter","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"2019111819264531000_B3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2141.2010.08365.x","article-title":"Cardiac magnetic resonance in transfusion dependent thalassaemia: assessment of iron load and relationship to left ventricular ejection fraction.","volume":"151","author":"Chouliaras","year":"2010","journal-title":"Br J Haematol"},{"key":"2019111819264531000_B4","unstructured":"Thalassaemia International Federation\n          Guidelines for the Clinical Management of Thalassaemia, 2nd Revised Edition. 2008. Available at: www.thalassaemia.org.cy\/wp-content\/uploads\/pdf\/educational-programmes\/Publications\/Guidelines%20%282008%29\/Thalassaemia%20Guidelines%20ENGLISH.pdf. Accessed May 11, 2015"},{"issue":"12","key":"2019111819264531000_B5","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1182\/blood-2009-04-217455","article-title":"Efficacy of deferasirox in reducing and preventing cardiac iron overload in \u03b2-thalassemia.","volume":"115","author":"Pennell","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111819264531000_B6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3324\/haematol.2010.031468","article-title":"Continued improvement in myocardial T2* over two years of deferasirox therapy in \u03b2-thalassemia major patients with cardiac iron overload.","volume":"96","author":"Pennell","year":"2011","journal-title":"Haematologica"},{"issue":"4","key":"2019111819264531000_B7","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2010-11-316646","article-title":"Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years\u2019 follow-up.","volume":"118","author":"Cappellini","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111819264531000_B8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00277-009-0838-z","article-title":"Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major.","volume":"89","author":"Pathare","year":"2010","journal-title":"Ann Hematol"},{"issue":"6","key":"2019111819264531000_B9","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3324\/haematol.2011.049957","article-title":"Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with \u03b2-thalassemia major.","volume":"97","author":"Pennell","year":"2012","journal-title":"Haematologica"},{"issue":"10","key":"2019111819264531000_B10","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1182\/blood-2013-04-497842","article-title":"A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in \u03b2-thalassemia major (CORDELIA).","volume":"123","author":"Pennell","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111819264531000_B11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2141.2004.05202.x","article-title":"Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance.","volume":"127","author":"Anderson","year":"2004","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111819264531000_B12","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2009-11-250308","article-title":"The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores.","volume":"116","author":"Wood","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111819264531000_B13","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.V95.4.1229.004k32_1229_1236","article-title":"Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk \u03b2-thalassemia.","volume":"95","author":"Davis","year":"2000","journal-title":"Blood"},{"key":"2019111819264531000_B14","article-title":"Efficacy and safety of a novel combination of two oral chelators deferasirox\/deferiprone over deferoxamine\/deferiprone in severely iron overloaded young beta thalassemia major patients [published online ahead of print January 20, 2015].","author":"Elalfy","journal-title":"Eur J Haematol"},{"key":"2019111819264531000_B15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1532-429X-10-12","article-title":"Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.","volume":"10","author":"Tanner","year":"2008","journal-title":"J Cardiovasc Magn Reson"},{"key":"2019111819264531000_B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1532-429X-15-1","article-title":"Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.","volume":"15","author":"Pepe","year":"2013","journal-title":"J Cardiovasc Magn Reson"},{"issue":"14","key":"2019111819264531000_B17","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","article-title":"A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.","volume":"115","author":"Tanner","year":"2007","journal-title":"Circulation"},{"issue":"2","key":"2019111819264531000_B18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bcmd.2012.10.006","article-title":"Combined chelation therapy with deferasirox and deferoxamine in thalassemia.","volume":"50","author":"Lal","year":"2013","journal-title":"Blood Cells Mol Dis"},{"key":"2019111819264531000_B19","author":"Ladis"},{"issue":"1","key":"2019111819264531000_B20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3324\/haematol.2012.070607","article-title":"Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine.","volume":"98","author":"Grady","year":"2013","journal-title":"Haematologica"},{"issue":"3","key":"2019111819264531000_B21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bcmd.2014.04.006","article-title":"Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.","volume":"53","author":"Cassinerio","year":"2014","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"2019111819264531000_B22","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/bjh.12517","article-title":"Impact of heart magnetic resonance imaging on chelation choices, compliance with treatment and risk of heart disease in patients with thalassaemia major.","volume":"163","author":"Origa","year":"2013","journal-title":"Br J Haematol"},{"issue":"23","key":"2019111819264531000_B23","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1053\/euhj.2001.2822","article-title":"Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload.","volume":"22","author":"Anderson","year":"2001","journal-title":"Eur Heart J"},{"issue":"2","key":"2019111819264531000_B24","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2004-01-0177","article-title":"Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance.","volume":"105","author":"St Pierre","year":"2005","journal-title":"Blood"},{"issue":"14","key":"2019111819264531000_B25","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.110.007641","article-title":"On T2* magnetic resonance and cardiac iron.","volume":"123","author":"Carpenter","year":"2011","journal-title":"Circulation"},{"issue":"6","key":"2019111819264531000_B26","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/jmri.20915","article-title":"Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron.","volume":"25","author":"Westwood","year":"2007","journal-title":"J Magn Reson Imaging"},{"issue":"7","key":"2019111819264531000_B27","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2008-04-148767","article-title":"Longitudinal analysis of heart and liver iron in thalassemia major.","volume":"112","author":"Noetzli","year":"2008","journal-title":"Blood"},{"key":"2019111819264531000_B28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1532-429X-15-38","article-title":"Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone.","volume":"15","author":"Porter","year":"2013","journal-title":"J Cardiovasc Magn Reson"},{"key":"2019111819264531000_B29","author":"Nichols-Vinueza"},{"issue":"1","key":"2019111819264531000_B30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jmri.22621","article-title":"Impact of magnetic resonance imaging on cardiac mortality in thalassemia major.","volume":"34","author":"Chouliaras","year":"2011","journal-title":"J Magn Reson Imaging"},{"issue":"5","key":"2019111819264531000_B31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1179\/102453311X13085644680302","article-title":"Retrospective epidemiological study of Latin American patients with transfusional hemosiderosis: the first Latin American epidemiological study in iron overload\u2014the RELATH study.","volume":"16","author":"Lobo","year":"2011","journal-title":"Hematology"},{"issue":"9","key":"2019111819264531000_B32","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00277-012-1465-7","article-title":"A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births.","volume":"91","author":"Voskaridou","year":"2012","journal-title":"Ann Hematol"},{"key":"2019111819264531000_B33","author":"Porter"},{"issue":"9","key":"2019111819264531000_B34","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","article-title":"Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.","volume":"107","author":"Pennell","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2019111819264531000_B35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ajh.23876","article-title":"Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.","volume":"90","author":"Pennell","year":"2015","journal-title":"Am J Hematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/25\/3868\/1386230\/3868.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/125\/25\/3868\/1386230\/3868.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:50:29Z","timestamp":1574124629000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/125\/25\/3868\/34292\/Effects-of-deferasiroxdeferoxamine-on-myocardial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,18]]},"references-count":35,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2015,6,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-07-586677","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,18]]}}}